Research reports mining丨 china merchants: Initiating coverage on beigene with a "strongly recommended" rating, bullish on the rapid expansion of products like zebutini in the short to medium term.
China Merchants Securities research reports point out that Beigene (688235.SH) is an international pharmaceutical company that has completed the global sales of innovative products. Its profound understanding of disease areas and scientific layout are fundamental to ensuring sustained competitiveness. Beigene's rapid growth in sales of products like Zebutini in the short to medium term is viewed as bullish, as is the competitiveness of its pipeline products in the medium to long term. The firm expects Beigene's revenue for 2024-2026 to be 26.87 billion yuan, 33.82 billion yuan, and 42.46 billion yuan respectively, with year-on-year growth of 54%, 26%, and 26%. Significant reduction in losses is anticipated in 2024, with profits for 2024-2026 projected to be a loss of 4.
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
Hong Kong stocks unusual movement | Beigene (06160) rose nearly 3% intraday as PRMT5 inhibitors approved for clinical use in China, expecting intensive catalysis next year.
Beigene (06160) rose nearly 3% during the session, as of the time of writing, it rose by 2.29%, closing at 120.5 Hong Kong dollars, with a turnover of 0.14 billion Hong Kong dollars.
China ADRs Have Increased to the Largest Share Since Late 2021 – GS
BeiGene Announces U.S. Regulatory Filing
Labcorp Holdings Names Julia Wang Chief Financial Officer, Effective Dec. 2 >LH
